Micromet to Present at Two Upcoming Investor Conferences

ROCKVILLE, Md.--()--Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that members of the Company’s management team will present a corporate overview at two upcoming investor conferences:

Goldman Sachs 32nd Annual Global Healthcare Conference
Thursday, June 9, 8 AM PT
Rancho Palos Verdes, CA

Jefferies 2011 Global Healthcare Conference
Thursday, June 9, 1 PM ET
New York, NY

The presentations will be webcast live and may be accessed by visiting the Micromet website at www.micromet.com. A replay of the webcasts will also be available on the Company's website.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.

Contacts

Micromet, Inc.
Jennifer Neiman
Director, Corporate Communications
240-235-0246
jennifer.neiman@micromet.com

Sharing

Contacts

Micromet, Inc.
Jennifer Neiman
Director, Corporate Communications
240-235-0246
jennifer.neiman@micromet.com